Organogenesis (ORGO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
24 Jun, 2026Opening remarks and agenda
Meeting called to order with a welcome and introduction of board and management team; meeting held virtually.
Agenda included formal business proceedings followed by a Q&A session.
Board and executive committee updates
Board members and executive management introduced, including roles and attendance.
April 23, 2026, set as the record date for voting eligibility.
Shareholder proposals
Only proposals listed in the meeting notice were considered; no additional matters brought forward by shareholders.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Organogenesis
- Q2 2026 revenue fell 58% and net loss widened to $96.3M amid ongoing market and regulatory disruption.ORGO
Q2 2026 - Q1 2026 revenue fell 58% and net loss widened amid CMS-driven disruption and restructuring.ORGOQ1 2026
- Director elections, executive pay, and auditor ratification headline a governance-focused annual meeting.ORGOProxy filing
- Record 2025 results, but 2026 revenue expected to decline amid CMS-driven disruption before recovery.ORGOQ4 2025
- Regulatory changes, new launches, and a robust pipeline position the company for strong future growth.ORGOCantor Global Healthcare Conference 2025
- Strong product innovation and regulatory adaptation drive growth amid reimbursement shifts.ORGO2024 Cantor Fitzgerald Global Healthcare Conference
- Q3 net income rose to $12.3M on 6% revenue growth; 2024 outlook strong despite regulatory risks.ORGOQ3 2024
- Q2 revenue up 11% to $130.2M, but net loss widened on impairments and write-downs.ORGOQ2 2024
- Q1 revenue dropped 21% and losses widened, but full-year guidance was reaffirmed.ORGOQ1 2025